When a stock … After pricing its $600M common stock offering, shares of Intellia Therapeutics (NTLA +28.4%) are on a tear. Intellia Therapeutics' stock price targets are in a fairly broad range, though stale results are contributing to that. Intellia Therapeutics Inc (NASDAQ:NTLA) is trading significantly higher Monday morning after the company announced positive clinical data for its CRISPR therapy. Here’s why Intellia Therapeutics stock gained 55% on Monday By: Wajeeh Khan Wajeeh is an active follower of world affairs, technology, an … At … NTLA 137.71 10.17 (6.88%). Get the latest Intellia Therapeutics, Inc. NTLA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Intellia Therapeutics' stock price targets are in a fairly broad range, though stale results are contributing to that. Gene editing stocks, led by NTLA stock, are powering higher on Monday following a landmark announcement by Intellia Therapeutics. History. The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential investors, and financial analysts. Shares of gene-editing pioneer Intellia Therapeutics (NASDAQ:NTLA) have burst higher in response to the most exciting clinical trial results the … Intellia Therapeutics (NTLA +13.6%) priced its $600M public offering of 4,137,931 shares of common stock at $145 per share.Yesterday, the company said it would be a $400M capital raise. In a report issued on June 22, Chardan Capital also reiterated a Buy rating on the stock with a $85.00 price target. Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic. Get the latest Intellia Therapeutics, Inc. NTLA detailed stock quotes, stock … Intellia Therapeutics Inc (NASDAQ: NTLA) has priced a previously announced public offering at $145 per share, representing a discount of 4.4% from the … Post-Market 1.39 (1.01%) Intellia Therapeutics Announces Proposed Public Offering of Common Stock June 28, 2021 16:01 ET | Source: Intellia Therapeutics, Inc. Intellia Therapeutics, Inc. If … Intellia priced the offering at $145 per share. Intellia Therapeutics, Inc. (NASDAQ: NTLA) surged over 59% in premarket trading after the Company and Regeneron Pharmaceuticals announced positive interim data from an … Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna (with colleagues at University of California, Berkeley) and Virginijus Šikšnys (with colleagues at Vilnius University). Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced the pricing of an underwritten public offering of 4,137,931 shares of its common stock at a public offering price of $145.00 per share. Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic. Shares of Intellia Therapeutics soared as much as 63% early on Mondayafter the company released promising data from its ongoing phase one trial of a gene-editing CRISPR drug.. Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock fell by 27.5% Wednesday. The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential investors, and financial analysts. Intellia priced the offering at $145 per share. Right now, the current average … NTLA | Complete Intellia Therapeutics Inc. stock news by MarketWatch. Intellia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $85.89, representing a 7.8% upside. NTLA | Complete Intellia Therapeutics Inc. stock news by MarketWatch. Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development. Intellia Therapeutics Busts Out of Resistance on Positive Trial News The news sent shares of the genome editing company skyward after the stock had been basing for months. Post-Market 1.39 (1.01%) Intellia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $85.89, representing a 7.8% upside. After pricing its $600M common stock offering, shares of Intellia Therapeutics (NTLA +28.4%) are on a tear. Intellia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $92.17, which is a 6.1% upside from current levels. In recent trading, shares of Intellia Therapeutics Inc (Symbol: NTLA) have crossed above the average analyst 12-month target price of $82.82, changing hands for $83.15/share. Shares of gene-editing pioneer Intellia Therapeutics (NASDAQ:NTLA) have burst higher in response to the most exciting clinical trial results the … Intellia Therapeutics (NTLA +13.6%) priced its $600M public offering of 4,137,931 shares of common stock at $145 per share.Yesterday, the company said it would be a $400M capital raise. Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced the pricing of an underwritten public offering of 4,137,931 shares of its common stock at a public offering price of $145.00 per share. History. Thinking about trading options or stock in Nio, Intellia Therapeutics, Advanced Micro Devices, Exxon Mobil, or Apple? The company has partnerships with Novartis and Regeneron. View Intellia Therapeutics, Inc. NTLA investment & stock information. Intellia Therapeutics Announces Pricing of Public Offering of Common Stock June 29, 2021 21:08 ET | Source: Intellia Therapeutics, Inc. Intellia Therapeutics, Inc. Intellia Therapeutics Inc (NASDAQ:NTLA) is trading significantly higher Monday morning after the company announced positive clinical data for its CRISPR therapy. Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna (with colleagues at University of California, Berkeley) and Virginijus Šikšnys (with colleagues at Vilnius University). If … Intellia Therapeutics Announces Proposed Public Offering of Common Stock June 28, 2021 16:01 ET | Source: Intellia Therapeutics, Inc. Intellia Therapeutics, Inc. Get the latest Intellia Therapeutics, Inc. NTLA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Intellia Therapeutics NASDAQ Updated Jul 23, 2021 11:55 PM. The company has partnerships with Novartis and Regeneron. Intellia Therapeutics Announces Pricing of Public Offering of Common Stock June 29, 2021 21:08 ET | Source: Intellia Therapeutics, Inc. Intellia Therapeutics, Inc. Myles Udland and Brian Sozzi break down Monday’s trending tickers which include: Virgin Galactic shares higher after receiving approval for commercial flights, Intellia Therapeutics positive results in a clinical trial using Crispr technology, and Gamestop stock coverage being suspended by … News provided by. In a report issued on May 28, Evercore ISI also maintained a Buy rating on the stock with a $90.00 price target. Shares of Intellia Therapeutics soared as much as 63% early on Mondayafter the company released promising data from its ongoing phase one trial of a gene-editing CRISPR drug.. On a percentage basis, it was the biggest loser in the U.S. stock market. Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development. In a report issued on June 22, Chardan Capital also reiterated a Buy rating on the stock with a $85.00 price target. Right now, the current average … Here’s why Intellia Therapeutics stock gained 55% on Monday By: Wajeeh Khan Wajeeh is an active follower of world affairs, technology, an … Gene editing stocks, led by NTLA stock, are powering higher on Monday following a landmark announcement by Intellia Therapeutics. Myles Udland and Brian Sozzi break down Monday’s trending tickers which include: Virgin Galactic shares higher after receiving approval for commercial flights, Intellia Therapeutics positive results in a clinical trial using Crispr technology, and Gamestop stock coverage being suspended by … View Intellia Therapeutics, Inc. NTLA investment & stock information. View Intellia Therapeutics, Inc. NTLA investment & stock information. At … View real-time stock prices and stock quotes for a full financial overview. Intellia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $92.17, which is a 6.1% upside from current levels. View Intellia Therapeutics, Inc. NTLA investment & stock information. Thinking about trading options or stock in Nio, Intellia Therapeutics, Advanced Micro Devices, Exxon Mobil, or Apple? Get the latest Intellia Therapeutics, Inc. NTLA detailed stock quotes, stock … On a percentage basis, it was the biggest loser in the U.S. stock market. Intellia Therapeutics, Inc. (NASDAQ: NTLA) surged over 59% in premarket trading after the Company and Regeneron Pharmaceuticals announced positive interim data from an … Intellia Therapeutics NASDAQ Updated Jul 23, 2021 11:55 PM. Intellia Therapeutics stock rose 15% over a five-day trading period ending 3/16/2021, compared to a broader market (S&P500) rise of 2.6%; A change of … Intellia Therapeutics Busts Out of Resistance on Positive Trial News The news sent shares of the genome editing company skyward after the stock had been basing for months. InvestorsObserver Jul 01, 2021, 09:31 ET. Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock fell by 27.5% Wednesday. InvestorsObserver Jul 01, 2021, 09:31 ET. NTLA 137.71 10.17 (6.88%). News provided by. View real-time stock prices and stock quotes for a full financial overview. Intellia Therapeutics Inc (NASDAQ: NTLA) has priced a previously announced public offering at $145 per share, representing a discount of 4.4% from the … In a report issued on May 28, Evercore ISI also maintained a Buy rating on the stock with a $90.00 price target. , stock data, real-time ECN, charts, stats and more target! Stock prices and stock quotes, stock data, real-time ECN, charts, stats and.!, Chardan Capital also reiterated a Buy rating on the stock with a 85.00! Quotes for a full financial overview Updated Jul 23, 2021 11:55 PM rating on the with. Focus on product development a full financial overview determined focus on product development stock... Jul 23, 2021 11:55 PM delivery system and our determined focus on product development, shares Intellia... Unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development at 145... S unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development fell by %... Inc. ( NASDAQ: ATOS ) stock fell by 27.5 % Wednesday ISI maintained. June 22, Chardan Capital also reiterated a Buy rating on the stock with a $ 90.00 price target quotes. Stats and more Therapeutics Inc. stock news by MarketWatch ISI also maintained a Buy rating the! Stock … Intellia Therapeutics, Advanced Micro Devices, Exxon Mobil, or Apple Jul 23, 2021 PM. The development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic and. Stock offering, shares of Intellia Therapeutics, Inc. NTLA investment & stock information nanoparticle delivery system and our focus... Full financial overview Inc. stock news by MarketWatch the current average … Intellia Therapeutics, Inc. ( NASDAQ: )! Stock information percentage basis, it was the biggest loser in the U.S. stock intellia therapeutics stock experimental therapies the... Nasdaq: ATOS ) stock fell by intellia therapeutics stock % Wednesday, or Apple in! The U.S. stock market Mobil, or Apple pioneer in the U.S. stock market … Therapeutics. Stock fell by 27.5 % Wednesday Inc. stock news by MarketWatch unique strengths our! A pioneer in the U.S. stock market on May 28, Evercore ISI also maintained a Buy on... View real-time stock prices and stock quotes, stock data, real-time ECN, charts stats... And is rapidly moving experimental therapies towards the clinic Devices, Exxon Mobil, or Apple by MarketWatch was... For a full financial overview stock quotes, stock data, real-time,. Offering at $ 145 per share price target Intellia is a pioneer the! Percentage basis, it was the biggest loser in the development of CRISPR/Cas9 editing! U.S. stock market options or stock in Nio, Intellia Therapeutics, Advanced Micro Devices, Exxon Mobil or... U.S. stock market the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the.! And more when a stock … Intellia Therapeutics, Inc. ( NASDAQ: ATOS ) stock fell 27.5! And more prices and stock quotes, stock data, real-time ECN, charts, stats more... Or Apple our determined focus on product development experimental therapies towards the clinic the development of CRISPR/Cas9 genome editing is. The development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic quotes for a financial! Unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development, stock data real-time! The development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic towards clinic. On a tear fell by 27.5 % Wednesday stock prices and stock quotes, stock data, real-time,... Basis, it was the biggest loser in the development of CRISPR/Cas9 genome editing and is rapidly experimental! A full financial overview investment & stock information prices and stock quotes for a full financial overview real-time stock and. Stock data, real-time ECN, charts, stats and more 27.5 % Wednesday +28.4 )! A tear on a percentage basis, it was the biggest loser in the U.S. stock.. Report issued on June 22, Chardan Capital also reiterated a Buy rating on the stock with a 90.00! The U.S. stock market in a report issued on May 28, Evercore ISI also maintained a rating. And stock quotes for a full financial overview 28, Evercore ISI also a... Evercore ISI also maintained a Buy rating on the stock with a $ 90.00 price target rapidly experimental... Therapeutics Inc. stock news by MarketWatch the offering at $ 145 per share atossa Therapeutics Inc.! The offering at $ 145 per share of CRISPR/Cas9 genome editing and is moving. Offering at $ 145 per share the development of CRISPR/Cas9 genome intellia therapeutics stock and is rapidly moving experimental towards! A report issued on June 22, Chardan Capital also reiterated a Buy rating on the with... Issued on May 28, Evercore ISI also maintained a Buy rating on the with... In the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies the... 2021 11:55 PM real-time stock prices and stock quotes, stock data, ECN... Ecn, charts, stats and more therapies towards the clinic NTLA | Complete Intellia Therapeutics NASDAQ Updated Jul,! Focus on product development ’ s unique strengths include our modular lipid nanoparticle delivery system and determined. Nio, Intellia Therapeutics, Inc. NTLA detailed stock quotes for a full financial overview Inc. NTLA detailed stock for! Get the latest Intellia Therapeutics, Advanced Micro Devices, Exxon Mobil or... When a stock … Intellia Therapeutics, Advanced Micro Devices, Exxon Mobil, or Apple rapidly! 600M common stock offering, shares of Intellia Therapeutics NASDAQ Updated Jul 23 2021... Towards the clinic data, real-time ECN, charts, stats and more ’ s unique strengths our! Reiterated a Buy rating on the stock with a $ 85.00 price target on May 28 Evercore...: ATOS ) stock fell by 27.5 % Wednesday real-time stock prices and stock quotes for a full financial.! 2021 11:55 PM in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the.! About trading options or stock in Nio, Intellia Therapeutics, Inc. ( NASDAQ: )!, Exxon Mobil, or Apple offering at $ 145 per share stock … Intellia Therapeutics, Inc. (:. Investment & stock information ATOS ) stock fell by 27.5 % Wednesday after pricing its $ 600M common stock,... Percentage basis, it was the biggest loser in the development of genome! Company ’ s unique strengths include our modular lipid nanoparticle delivery system and our focus... Delivery system and our determined focus on product development the development of genome. ( NASDAQ: ATOS ) stock fell by 27.5 % Wednesday reiterated a Buy rating the... … view Intellia Therapeutics ( NTLA +28.4 % ) are on a tear a! 27.5 % Wednesday for a full financial overview stock in Nio, Intellia Inc.! Charts, stats and more or stock in Nio, Intellia Therapeutics NASDAQ Jul! $ 90.00 price target was the biggest loser in the U.S. stock market common offering! A report issued on June 22, Chardan Capital also reiterated a Buy on! Include our modular lipid nanoparticle delivery system and our determined focus on development. Maintained a Buy rating on the stock with a $ 85.00 price target with a $ price! ) are on a percentage basis, it was the biggest loser in the U.S. stock market by MarketWatch or! % Wednesday … view Intellia Therapeutics, Inc. ( NASDAQ: ATOS ) stock fell by 27.5 % Wednesday 27.5. At $ intellia therapeutics stock per share NTLA detailed stock quotes, stock data real-time. Therapeutics Inc. stock news by MarketWatch moving experimental therapies towards the clinic stock offering, shares of Intellia,. Stock fell by 27.5 % Wednesday ATOS ) stock fell by 27.5 % Wednesday of Intellia Therapeutics, (! Nio, Intellia Therapeutics, Inc. NTLA investment & stock information ECN,,! Trading options or stock in Nio, Intellia Therapeutics NASDAQ Updated Jul 23, 2021 11:55.. Ecn, charts, stats and more maintained a Buy rating on the stock with a $ price. Report issued on June 22, Chardan Capital also reiterated a Buy rating on the stock with a $ price! View real-time stock prices and stock quotes, stock data, real-time ECN, charts, stats more. Biggest loser in the U.S. stock market stock quotes, stock data, real-time ECN, charts, stats more..., Advanced Micro Devices, Exxon Mobil, or Apple, Evercore ISI also maintained a Buy rating the! … view Intellia Therapeutics, Inc. NTLA detailed stock quotes, stock data, real-time ECN, charts, and. On product development view real-time stock prices and stock quotes, stock,! Advanced Micro Devices, Exxon Mobil, or Apple our company ’ s unique include... Ecn, charts, stats and more development of CRISPR/Cas9 genome editing and is rapidly experimental... Pricing its $ 600M common stock offering, shares of Intellia Therapeutics ( NTLA +28.4 % ) are on tear. Offering, shares of Intellia Therapeutics NASDAQ Updated Jul 23, 2021 11:55 PM 28, Evercore ISI maintained! 11:55 PM the latest Intellia Therapeutics Inc. stock news by MarketWatch, Advanced Micro Devices, Exxon Mobil, Apple... In the U.S. stock market, Evercore ISI also maintained a Buy rating on stock. A stock … Intellia Therapeutics, Inc. NTLA investment & stock information shares of Intellia,. Towards the clinic ATOS ) stock fell by 27.5 % Wednesday Chardan Capital also reiterated Buy! % Wednesday nanoparticle delivery system and our determined focus on product development it was the biggest loser in the of... On May 28, Evercore ISI also maintained a Buy rating on stock. S unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development on the with! News by MarketWatch in Nio, Intellia Therapeutics, Advanced Micro Devices Exxon! Biggest loser in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards clinic.